Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 9 shares, a decline of 97.0% from the April 30th total of 300 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 2,945 shares, the short-interest ratio is currently 0.0 days.

Enzon Pharmaceuticals Trading Up 2.6%

Enzon Pharmaceuticals stock traded up $0.15 during trading hours on Wednesday, hitting $5.95. The company had a trading volume of 735 shares, compared to its average volume of 1,181. The firm has a market cap of $4.40 million, a P/E ratio of -0.87 and a beta of -0.03. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.16 and a current ratio of 2.01. Enzon Pharmaceuticals has a 1 year low of $1.50 and a 1 year high of $12.99. The company has a 50-day moving average price of $6.07 and a two-hundred day moving average price of $5.51.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last released its quarterly earnings data on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $86.54 million for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.